About ADUHELM
ADUHELM attaches to and reduces amyloid plaques, a buildup of proteins in the brains of people with mild cognitive impairment (MCI) or mild dementia stage of Alzheimer’s disease.
Ask your doctor if ADUHELM is right for you.
What are amyloid plaques?
Amyloid plaques are clumps of protein that may:
- Build up in the brain over time
- Begin appearing long before symptoms occur
- Lead to the loss of brain function
Amyloid plaques are a key
feature of Alzheimer’s.
Your doctor will decide if you need further testing to check the levels of amyloid plaques in your brain.
How ADUHELM works
ADUHELM works inside
the brain
Amyloid plaques building
up in
the brain is one
component of
Alzheimer’s.
ADUHELM binds
to amyloid
plaques
in the brain.
Then ADUHELM helps remove
some of the amyloid to reduce
the
amount of plaques in the brain.
These images are for illustrative purposes only. They are not meant to exactly represent the brain or all components that may contribute to the loss of brain function in Alzheimer’s.
ADUHELM is indicated for the treatment of Alzheimer’s disease. ADUHELM should be started in patients with mild cognitive impairment or mild dementia stage of disease, the population studied in clinical trials. There are no data on risks or benefits for patients in other stages of Alzheimer’s. ADUHELM is approved under accelerated approval based on reduction in amyloid plaques as seen in patients treated with ADUHELM. Continued approval of ADUHELM may require verification of clinical benefit in a confirmatory study
Continue: